4.7 Review

Liposome-Based Drug Delivery Systems in Cancer Immunotherapy

Journal

PHARMACEUTICS
Volume 12, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics12111054

Keywords

liposome; drug delivery; cancer immunotherapy; immunomodulation

Funding

  1. China Scholarship Council [CSC201906100211]
  2. H2020-MSCA-Intra European Fellowship-2018 [832455-Need2immune]
  3. VIDI personal grant [723.012.110]
  4. European Commission H2020-MSCA-RISE [644373-PRISAR, 777682-CANCER, 807281-ACORN, 852985-SIMICA, 734684 -CHARMED, 675743 -ISPIC, 861190, 857894, 859908, 860173, 872860]
  5. Marie Curie Actions (MSCA) [857894, 859908, 861190, 872860, 860173] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such as liposomes, have favorable advantages with the potential to further improve cancer immunotherapy and even stronger immune responses by improving cell type-specific delivery and enhancing drug efficacy. Liposomes can offer solutions to common problems faced by several cancer immunotherapies, including the following: (1) Vaccination: Liposomes can improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells; (2) Tumor normalization: Liposomes can deliver drugs selectively to the tumor microenvironment to overcome the immune-suppressive state; (3) Rewiring of tumor signaling: Liposomes can be used for the delivery of specific drugs to specific cell types to correct or modulate pathways to facilitate better anti-tumor immune responses; (4) Combinational therapy: Liposomes are ideal vehicles for the simultaneous delivery of drugs to be combined with other therapies, including chemotherapy, radiotherapy, and phototherapy. In this review, different liposomal systems specifically developed for immunomodulation in cancer are summarized and discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available